IBRX — ImmunityBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1326110 ·
Last close
$8.44
Market Cap
$8.95B
52W High
$12.43
52W Low
$1.95
ADV30
9,616,873
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 51,240,000 | 50,942,000 | -61,697,000 | -230,378,000 | 628,504,000 | 75,670,000 | 1,674,265,000 |
| Mar 2026 | 44,206,000 | 43,968,000 | -69,791,000 | -632,782,000 | 646,637,000 | 205,194,000 | 1,515,763,000 |
| Dec 2025 | 38,285,000 | 37,903,000 | -64,683,000 | -61,944,000 | 501,898,000 | 88,334,000 | 1,001,472,000 |
| Sep 2025 | 32,061,000 | 31,884,000 | -55,630,000 | -67,253,000 | 518,987,000 | 60,241,000 | 1,042,397,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-281,138,000
Investing CF
$-276,907,000
Financing CF
$496,782,000
CapEx
$-7,376,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.97
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,589,806,000
Inventory
$1,940,000
Receivables
$53,499,000
ST Investments
$281,701,000
EBIT TTM
$-878,096,000
Pretax Income TTM
$-992,580,000
Interest Exp TTM
$114,484,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$165,792,000
EBITDA
$-235,298,000
Free Cash Flow
$-186,564,128
Enterprise Value
$9,255,202,816
Total Cash
$357,371,008
Total Debt
$1,228,401,024
Shares Out
1,059,836,273
Trailing EPS
$-0.95
Book Value
$-0.99
ROE
—
ROA
-30.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 113,288,000 | -256,027,000 | -351,398,000 | 501,898,000 | 1,001,472,000 | -500,469,000 | -304,936,000 |
| Dec 2024 | 14,745,000 | -344,182,000 | -413,564,000 | 382,933,000 | 871,062,000 | -489,098,000 | -391,236,000 |
| Dec 2023 | 622,000 | -361,364,000 | -583,196,000 | 504,452,000 | 1,090,389,000 | -586,987,000 | -366,757,000 |
| Dec 2022 | 240,000 | -350,617,000 | -416,567,000 | 362,356,000 | 812,176,000 | -447,327,000 | -337,509,000 |
TTM Snapshot
Revenues TTM
$22,823,000
NetIncome TTM
$-421,895,000
OpCashFlow TTM
$0
Assets (Latest)
$501,898,000
Forward EPS
$-0.13
Max Pain — expiry 2026-10-02
max pain strike: $8.50 · spot: $8.84 · call oi: 6,264 · put oi: 4,037
Expected Move to 2026-10-02:
±$0.85
(9.62%) —
implied range
$7.99 –
$9.69
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QGEN | QIAGEN N.V. | $9.12B | $44.18 | — |
| KYMR | Kymera Therapeutics, Inc. | $9.21B | $111.95 | — |
| PCVX | Vaxcyte, Inc. | $8.36B | $56.21 | — |
| KRYS | Krystal Biotech, Inc. | $10.24B | $345.82 | — |
| RGEN | REPLIGEN CORP | $10.70B | $189.68 | — |
News headlines (Yahoo Finance, 1h cache)
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
2026-09-23 00:26 · Yahoo
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
2026-09-21 06:49 · Yahoo
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
2026-09-18 07:41 · Yahoo
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
2026-09-15 04:00 · Yahoo
IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet
2026-09-14 23:29 · Yahoo
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck
2026-09-14 08:47 · Yahoo
IBRX Stock Eyes Worst Week Since July: New Patent Eyes Broader Anktiva Use Ahead Of Lung Cancer Conference
2026-09-11 08:04 · Yahoo
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
2026-09-10 03:03 · Yahoo
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
2026-09-01 06:09 · Yahoo
IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update
2026-08-27 17:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.